The average one-year price target for Indaptus Therapeutics (NASDAQ:INDP) has been revised to 10.20 / share. This is an increase of 25.00% from the prior estimate of 8.16 dated October 31, 2023. The ...
CEO and Director of Indaptus Therapeutics Inc (30-Year Financial, Insider Trades) Jeffrey A Meckler (insider trades) bought 12,000 shares of INDP on 09/14/2021 at an average price of $7 a share. The ...
Detailed price information for Indaptus Therapeutics Inc (INDP-Q) from The Globe and Mail including charting and trades.
Short interest in Indaptus Therapeutics Inc (NASDAQ:INDP) decreased during the last reporting period, falling from 119.93K to 81.07K. This put 0.71% of the company's publicly available shares short.
Indaptus Therapeutics INDP announced positive data from pre-clinical studies that demonstrated the efficacy of Decoy, its bacteria-based immunotherapy platform technology. The data was presented in a ...
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...
On Tuesday, Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced it advanced to a new expansion arm of its Phase 1b/2 clinical trial of Decoy20. The expansion will evaluate the combination of Decoy20 ...
Indaptus Therapeutics Inc. Annual cash flow by MarketWatch. View INDP net cash flow, operating cash flow, operating expenses and cash dividends.
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Indaptus Therapeutics ( (INDP)) just ...
In a challenging market environment, Intec Pharma Ltd (NASDAQ: INDP) stock has reached its 52-week low, trading at $1.02. This price level reflects a significant downturn for the company, which has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results